John Phillips, MD
Gastroenterology · Tupelo, MSNPI 1023077732
Payments from drug & device makers
Across 722 payments — averaging $217.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$95K
- Madrigal Pharmaceuticals$30K
- AbbVie$17K
- Ipsen Biopharmaceuticals, Inc$7K
- Eli Lilly$2K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$2K
- plus $5K from 31 others
What the payments were for
- Speaking & faculty fees$125,23084%
- Travel & lodging$10,4667%
- Food & beverage$13,6839%
- Education$1270%
- Gifts$3000%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 131 | $94,589 |
| Madrigal Pharmaceuticals | 37 | $29,786 |
| AbbVie(2 entities) | 173 | $16,623 |
| Ipsen Biopharmaceuticals, Inc | 8 | $7,498 |
| Eli Lilly | 2 | $1,833 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 118 | $1,619 |
| Intercept Pharmaceuticals, Inc. | 46 | $783 |
| Takeda Pharmaceuticals U.S.A., Inc. | 34 | $553 |
| Sanofi | 19 | $423 |
| Intra-sana Laboratories | 3 | $357 |
| Johnson & Johnson | 16 | $341 |
| Phathom Pharmaceuticals, Inc. | 9 | $311 |
| QOL Medical, LLC | 14 | $277 |
| Mallinckrodt Hospital Products Inc. | 9 | $193 |
| Regeneron Healthcare Solutions, Inc. | 8 | $185 |
| Ardelyx, Inc. | 8 | $177 |
| Merck | 11 | $174 |
| Daiichi Sankyo Inc. | 11 | $170 |
| Ironwood Pharmaceuticals, Inc | 10 | $156 |
| Nestle Healthcare Nutrition Inc. | 8 | $140 |
| Bristol Myers Squibb | 7 | $111 |
| Evoke Pharma, Inc. | 2 | $110 |
| Aimmune Therapeutics, Inc. | 7 | $101 |
| Braintree Laboratories, Inc. | 5 | $100 |
| Boston Scientific | 5 | $91 |
| Dova Pharmaceuticals | 1 | $60 |
| Pfizer | 4 | $58 |
| Fresenius Kabi USA, LLC | 3 | $53 |
| Celltrion USA Inc. | 1 | $43 |
| Biocompatibles, Inc. | 2 | $42 |
| Enterra Medical, Inc. | 2 | $42 |
| Amgen | 2 | $40 |
| Lilly USA, LLC | 2 | $34 |
| Ferring Pharmaceuticals Inc. | 1 | $19 |
| AMAG Pharmaceuticals, Inc. | 1 | $15 |
| Medtronic | 1 | $12 |
| Organon | 1 | $5 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Epclusa$62,302
- REZDIFFRA$29,103
- Livdelzi$24,922
- Mavyret$8,788
- Reltone 200 Mg$300
- Reltone 400 Mg$300
- VOQUEZNA$105
How this compares
$157,121 in reported general payments places this provider in the 90th percentile of 127 gastroenterology providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EpclusaSofosbuvir/Velpatasvir | 14 | $338,915 |
| OcalivaObeticholic Acid | 29 | $278,675 |
| Sofosbuvir-VelpatasvirSofosbuvir/Velpatasvir | 11 | $89,920 |
| VemlidyTenofovir Alafenamide | 17 | $23,155 |
| CreonLipase/Protease/Amylase | 16 | $18,137 |
| LinzessLinaclotide | 26 | $13,760 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 188 | $12,229 |
| Ursodiol | 98 | $8,216 |
| MotegrityPrucalopride Succinate | 14 | $7,075 |
| Tenofovir Disoproxil Fumarate | 19 | $3,969 |
| Dexlansoprazole DrDexlansoprazole | 23 | $3,806 |
| Lansoprazole | 153 | $2,330 |
| SutabSod Sulf/Pot Chloride/Mag Sulf | 14 | $2,260 |
| FenofibrateFenofibrate Nanocrystallized | 54 | $1,378 |
| SuflavePeg 3350/Sod Sulf,chlr/Pot/Mag | 11 | $1,318 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadEpclusa, Vemlidy | $94,589 | $362,07031 claims |
| Intercept Pharmaceuticals, Inc.Ocaliva | $783 | $278,67529 claims |
| AbbVieCreon, Linzess | $16,623 | $31,89742 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Motegrity | $553 | $7,07514 claims |
| Braintree Laboratories, Inc.Sutab, Suflave | $100 | $3,57825 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 127 gastroenterology providers in Mississippi.
Other gastroenterology in Tupelo
- Stephen AmannTupelo$13K
- Christopher DeckerTupelo$6K
- Brian BorgJackson$1.7M
- Reed HoganFlowood$761K
- John RunnelsFlowood$591K
- Nabeel KhanSouthaven$552K
- Wassem JuakiemBiloxi$519K
- Stephen BuckleyHattiesburg$372K
- Reed HoganFlowood$369K
- Jane Claire WilliamsFlowood$271K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.